Exchange Traded Concepts LLC boosted its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 191.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,101 shares of the company's stock after purchasing an additional 27,019 shares during the period. Exchange Traded Concepts LLC owned about 0.09% of Structure Therapeutics worth $1,804,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its position in Structure Therapeutics by 498.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 427,735 shares of the company's stock valued at $17,434,000 after purchasing an additional 356,302 shares during the last quarter. Wellington Management Group LLP increased its holdings in Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company's stock worth $178,216,000 after buying an additional 3,504,747 shares during the last quarter. TrueMark Investments LLC raised its position in Structure Therapeutics by 13.5% during the first quarter. TrueMark Investments LLC now owns 29,884 shares of the company's stock valued at $1,281,000 after acquiring an additional 3,562 shares in the last quarter. FORA Capital LLC acquired a new stake in Structure Therapeutics in the first quarter valued at approximately $732,000. Finally, Capital International Investors grew its position in Structure Therapeutics by 50.8% in the first quarter. Capital International Investors now owns 1,281,564 shares of the company's stock worth $54,928,000 after acquiring an additional 431,540 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.
Structure Therapeutics Stock Performance
Shares of NASDAQ:GPCR traded up $2.69 on Wednesday, hitting $38.99. 934,797 shares of the company were exchanged, compared to its average volume of 788,105. The company's 50 day moving average price is $39.02 and its two-hundred day moving average price is $39.89. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -50.82 and a beta of -3.53. Structure Therapeutics Inc. has a one year low of $26.61 and a one year high of $75.02.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. Research analysts predict that Structure Therapeutics Inc. will post -0.79 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on GPCR shares. JMP Securities decreased their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a report on Friday, August 9th. Morgan Stanley began coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $87.83.
Get Our Latest Report on GPCR
Structure Therapeutics Company Profile
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Further Reading
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
